Clinical Trial Update: Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Open-label extension safety study of PROCRIT (epoetin alfa) in anemia of chronic disease due to rheumatoid arthritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Anemia of Chronic Disease
• Rheumatoid Arthritis

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Ortho Biotech Products, L.P. | Conditions: Anemia, Rheumatoid Arthritis | Phase 2 | Status: WITHDRAWN